Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07412288 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
A Phase 1 study of Healthy Participants, sponsored by Kymera Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT07412288: Recruiting Phase 1 study of Healthy Participants, sponsored by Kymera Therapeutics.
NCT07412288 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 96 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07412288, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Kymera Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KT-579
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT07412288 shows while recruiting
NCT07412288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07412288 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT07412288 about?
NCT07412288 is a clinical study titled "First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants". This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
What is the current status of trial NCT07412288?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2026-02-23. Estimated completion is 2026-12.
What conditions does trial NCT07412288 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07412288?
The interventions under investigation include: Placebo (DRUG), KT-579 (DRUG).
Who is sponsoring clinical trial NCT07412288?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07412288 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07412288's enrollment target sits among peer trials
96 26th of 119 higher than 94 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI